Procalcitonin to guide (reduce) antibiotic use: meta-analysis, reviews - PulmCCM
Advertisement
Aug 212011
 

Schuetz et al review the 16 randomized controlled trials (n=4,647) testing procalcitonin-guided vs. standard care on the outcomes of antibiotic use, mortality, and infection control. Most of these studies were done in Europe; 6 were in ICU patients. Using procalcitonin reduced antibiotic use in all settings (primary care, emergency department, ICU) with no detectable differences in mortality. Arch Int Med 2011;171:1322-1331.

In a separate systematic review, Agarwal and Schwartz describe the 6 aforementioned randomized controlled trials (n=1,476) assessing the use of serum procalcitonin to guide antimicrobial decisions in the ICU. All 5 that measured duration of antibiotic therapy found a reduction of 20-38% with procalcitonin guidance. Length of stay was lower in 2 studies. There were no differences in mortality or infection relapse. Clin Infect Dis 2011;53:379-387.

Procalcitonin offers major promise in reducing the burden of excessive antimicrobial use. Is procalcitonin-guided therapy ready for broader use in the ICU and the community? At a minimum, we physicians could use guidance as to the best cutoff values to guide decision making. The general strategy in the ICU studies was to:

  • Measure procalcitonin serially, and stop antibiotics when levels had fallen 80-90% or to 0.25-0.50 mcg/L.
  • Antibiotic use was encouraged in general when procalcitonin was above 0.50 mcg/L, and strongly encouraged above 1.0 mcg/L.

A randomized trial showed harm from use of procalcitonin-driven antimicrobial strategies in Crit Care Med 2011, but they used 1.0 ng/mL as the cutoff to intensify therapy (not 0.5).

Liked this post? Get a weekly email update (no spam, ever), and explore our library of pulmonary and critical care guidelines, practice updates and review articles.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society and/or journal referenced on the website.

Leave a Comment